Worldwide Innovative Networking in personalized cancer medicine WINConsortium= invites you to the 3rd WIN Symposium • 6th-8th J= uly, 2011• Palais des Congrès de Paris [France]The 3rd WIN Symposium, E.O.R.T.C. endorsed, brings wo=rldwide pharma, biotech, and academics together to address the rapidlyadvancing field of personalized cancer me= dicine. WIN announces aunique scientific program (www.winconsortium.org/program ). TheWIN Symposium will inaugurate an unprecedented fo= rmat, where pharma,biotech, academia and patient organizations will be giving their viewson how to address the chal= lenges of efficacy of cancer diagnosticsand therapeutics in the era of personalized healthcare, to the benefitof the pat= ient.= “We aim to create a forum for open discussion i= n which theexpertise and input from all stakeholders in targeted cancer drugdevelopment are crucial” said Dr. JohnMendelsohn, ! ;Chairman of the WIN Consortium and President of the U=niversity of Texas MD Anderson Cancer Center.Outstanding speakers will be leading this unique eve= nt:pharma and biotech Mike Burgess, Robert Wasserman and Peter-Ulrich Rohr= (Roche), Gary Gilliland (Merck and Co), Nick Botwood (AstraZeneca),Shannon Morris (GlaxoSmithKline= ), Samit Hirawat (Novartis), AntonellaIsacchi and Artur= o Galvani (Nerviano Medical Sciences), Paul Billingsand Martin Naley (Life Technologies), Leo Bonilla (AgilentTechnologies) and Ian Wilson (GE= Healthcare). academia and patientorganizations John Mendelsohn, Razelle Kurzrock and Donald Berry (U=T-MD Anderson Cancer Center), Samir Hanash (Fred Hutchinson CancerCenter), Leroy Hood (Institut= for Systems Biology Seattle), DavidSidransky (Johns = Hopkins University), Stephen Friend (SageBionetworks), Keneth Anderson (Dana Farber Cancer Institute), AlexanderEggermont and Jean-Charles Soria (Institut = Gustave Roussy), Janell! eHail (National Breast Cancer Foundation), Julio E. Celis (DanishCancer Society), Denis Lacombe (EORTC), Robert Kerbel (Sunnybrook Heal=th Sciences Center), Dominique Stoppa-Lyonnet (Institut Curie) and manyothers.Topics addressed:= • Evidence for efficacy of targeted therapeutics= •Improving the efficacy of biomarker-driven clinical trials • C=ombinations of targeted drugs • Discovering and validating newtargets and pre= dictive biomarkers • Advances in technology,bioinformatics and system= s biology • Strategic alliances tofight cancer= “A synthesis of the symposium, will be presente= d by Dr.Richard L. Schilsky, Chairman of the WIN Scientific Advisory Board,aiming to present concrete perspectives to improve cl= inical outcomesand the quality of life for cancer patients worldwide” saysVladimir Lazar, WIN Chief Operating OfficerRegister now on http://www.winconsortium.org Contacts Vladimir! Lazar, Chief Operating Officer: vladimir.lazar@igr= .fr Tel: +3314! 2 11 40 20 Catherine Bresson, Director of Operational Team: [email protected] unsubscribe or change your subscription options, please contact:newsletterWIN
